These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 19223637)

  • 1. Apricitabine does not select additional drug resistance mutations in tissue culture in human immunodeficiency virus type 1 variants containing K65R, M184V, or M184V plus thymidine analogue mutations.
    Oliveira M; Moisi D; Spira B; Cox S; Brenner BG; Wainberg MA
    Antimicrob Agents Chemother; 2009 Apr; 53(4):1683-5. PubMed ID: 19223637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity.
    White KL; Margot NA; Wrin T; Petropoulos CJ; Miller MD; Naeger LK
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3437-46. PubMed ID: 12384348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation.
    García-Lerma JG; MacInnes H; Bennett D; Reid P; Nidtha S; Weinstock H; Kaplan JE; Heneine W
    J Virol; 2003 May; 77(10):5685-93. PubMed ID: 12719561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.
    Bradshaw D; Malik S; Booth C; Van Houtte M; Pattery T; Waters A; Ainsworth J; Geretti AM
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4489-91. PubMed ID: 17876005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine.
    Cahn P; Wainberg MA
    J Antimicrob Chemother; 2010 Feb; 65(2):213-7. PubMed ID: 20007333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine.
    Paolucci S; Baldanti F; Campanini G; Cancio R; Belfiore A; Maga G; Gerna G
    Antiviral Res; 2007 Nov; 76(2):99-103. PubMed ID: 17640745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy.
    Betancor G; Garriga C; Puertas MC; Nevot M; Anta L; Blanco JL; Pérez-Elías MJ; de Mendoza C; Martínez MA; Martinez-Picado J; Menéndez-Arias L; ; Iribarren JA; Caballero E; Ribera E; Llibre JM; Clotet B; Jaén A; Dalmau D; Gatel JM; Peraire J; Vidal F; Vidal C; Riera M; Córdoba J; López Aldeguer J; Galindo MJ; Gutiérrez F; Álvarez M; García F; Pérez-Romero P; Viciana P; Leal M; Palomares JC; Pineda JA; Viciana I; Santos J; Rodríguez P; Gómez Sirvent JL; Gutiérrez C; Moreno S; Pérez-Olmeda M; Alcamí J; Rodríguez C; del Romero J; Cañizares A; Pedreira J; Miralles C; Ocampo A; Morano L; Aguilera A; Garrido C; Manuzza G; Poveda E; Soriano V
    Retrovirology; 2012 Aug; 9():68. PubMed ID: 22889300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations.
    Parikh UM; Bacheler L; Koontz D; Mellors JW
    J Virol; 2006 May; 80(10):4971-7. PubMed ID: 16641288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
    Marcelin AG; Delaugerre C; Wirden M; Viegas P; Simon A; Katlama C; Calvez V
    J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. R211K and L214F do not invariably confer high level phenotypic resistance to thymidine analogs in zidovudine-naive patients with M184V.
    Torti C; Gilleece Y; Hertogs K; Gazzard BG; Pozniak AL
    J Acquir Immune Defic Syndr; 2001 Apr; 26(5):514-5. PubMed ID: 11391177
    [No Abstract]   [Full Text] [Related]  

  • 11. Trends in HIV-1 reverse transcriptase resistance-associated mutations and antiretroviral prescription data from 2003-2010.
    Miller MD; Haddad M; Su C; Gibbs C; McColl DJ; Guyer B
    Antivir Ther; 2012; 17(6):993-9. PubMed ID: 22837442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
    Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its inhibition by efavirenz.
    Crespan E; Locatelli GA; Cancio R; Hübscher U; Spadari S; Maga G
    Antimicrob Agents Chemother; 2005 Jan; 49(1):342-9. PubMed ID: 15616314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile.
    Yang G; Paintsil E; Dutschman GE; Grill SP; Wang CJ; Wang J; Tanaka H; Hamasaki T; Baba M; Cheng YC
    Antimicrob Agents Chemother; 2009 Nov; 53(11):4640-6. PubMed ID: 19704131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
    Miller V; Stürmer M; Staszewski S; Gröschel B; Hertogs K; de Béthune MP; Pauwels R; Harrigan PR; Bloor S; Kemp SD; Larder BA
    AIDS; 1998 May; 12(7):705-12. PubMed ID: 9619801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The balance between NRTI discrimination and excision drives the susceptibility of HIV-1 RT mutants K65R, M184V and K65r+M184V.
    Ly JK; Margot NA; MacArthur HL; Hung M; Miller MD; White KL
    Antivir Chem Chemother; 2007; 18(6):307-16. PubMed ID: 18320935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics of inhibition of HIV type 1 reverse transcriptase-bearing NRTI-associated mutations by apricitabine triphosphate.
    Frankel FA; Coutsinos D; Xu H; Wainberg MA
    Antivir Chem Chemother; 2007; 18(2):93-101. PubMed ID: 17542154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
    Izopet J; Bicart-See A; Pasquier C; Sandres K; Bonnet E; Marchou B; Puel J; Massip P
    J Med Virol; 1999 Dec; 59(4):507-11. PubMed ID: 10534734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine.
    Brehm JH; Koontz D; Meteer JD; Pathak V; Sluis-Cremer N; Mellors JW
    J Virol; 2007 Aug; 81(15):7852-9. PubMed ID: 17507476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations.
    Miranda LR; Götte M; Liang F; Kuritzkes DR
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2648-56. PubMed ID: 15980332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.